News zum Sektor Gesundheit aus Norwegen

 

Oslo, 5 February 2026: On the basis of the authorization granted by the General Meeting on 29 April 2025 for the Board of Directors of Zelluna ASA (the “Company”, OSE ticker “ZLNA”) to issue shares to employees and board members under a long-term incentive program, the Board of Directors has resolved to grant share options to two employees in the Company....

Oslo, Norway, February 5, 2025 – Lytix Biopharma AS (“Lytix” or the “Company”) will release its fourth quarter 2025 financial results and publish its second half 2025 financial report on Thursday, February 12, 2025.   Join us for a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein, where they will discuss the Q4 results and provide key insights.   Date: Thursday, February 12, 2025 Time: 10:00 AM CET   Q&A Session: We welcome your questions in advance. Please send them to post@lytixbiopharma.com, and they will be addressed during the Q&A...

GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million....

The Company will host a virtual Q4 and 12M 2025 presentation for investors, analysts and media at 10:00 CET on Thursday, 12 February, 2026. The presentation will be given by CEO, Michael Akoh, CCO, Paul Blackburn and CFO, Børge Sørvoll. The presentation can be followed as a live webcast from Hegnar TV on https://qcnl.tv/p/XRgPIoZrlRfhnjAmevVbeQ  or www.arcticzymes.com. It will be possible to post questions through the webcast console. The company is also pleased to announce it will host a Capital Markets Day Friday 6th March from 0900-1200, in Stockholm. More information will be...

Oslo, Norway, 5 February 2026...

Oslo, Norway, 5 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a webcast presentation of its fourth quarter 2025 results on Thursday, 12 February 2026....

Oslo, Norway, 03 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced the promotion of Emilie Gauthy to Chief Technology Officer (CTO). Gauthy, who has played a central role in building Zelluna's manufacturing and CMC capabilities since joining in 2022, assumes the role with immediate effect....

Oslo (Norway), 29 January 2026 – PCI Biotech (OSE: PCIB) refers to its latest announcement of 8 January 2026 regarding the discontinuation of all R&D operations and the continued exploration of strategic alternatives....

Arctic Bioscience are pleased to announce that we have been invited to present at the Glaucoma 360 New Horizons Forum in San Francisco on January 30th 2026, in the session 'The Perfect Dose: Innovating Drugs and Drug Delivery'. Our Medical Director, Runhild Gammelsæter, will be presenting our latest pipeline project, ABS403, with the aim to promote resolution of inflammation and support neuroprotection in glaucoma. This eye disease does not currently have a cure and leads to blindness. The project was initiated based on encouraging clinical signals from a pilot study in glaucoma (POAG)....

· First patient enrolled in newly activated site Oslo, Norway, 29 January 2026: Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announces that the first patient has been enrolled at one of the newly activated sites in its Phase 2 study of Radspherin[®] in patients with peritoneal carcinomatosis from ovarian cancer. The randomized part of the study has been actively recruiting patients at six sites since March 2025. Four additional sites have now been opened, and the first patient has been enrolled at one of these newly...

Die Aktie des schwedischen Biotech-Unternehmens Camurus hat sich in den zurückliegenden Monaten sehr volatil entwickelt. Die Analysten von ABG Sundal Collier (ABGSC) trauen dem Papier allerdings neue Rekorde zu. DER AKTIONÄR erklärt, was jetzt für einen Kauf der Anteile der Skandinavier spricht, die unter anderem mit dem Pharma-Riesen Eli Lilly zusammenarbeiten....

Oslo, Norway, 20 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 January 2026 regarding the Company's extraordinary general meeting resolving a reverse share split of the Company's shares in the ratio 100:1. The reverse share split has today been registered with the Norwegian Register of Business Enterprises. Following the registration, the share capital of the Company is NOK 223,920,600 divided into 4,478,412 shares, each with a nominal value of NOK 50....

Issuer name: Oncoinvent ASA Ex. date: 19 January 2026 Type of corporate action: Reverse share split Other information: - Reverse split ratio: 100:1, i.e. one hundred (100) old shares give one (1) new share - New par value per share: NOK 50 - New ISIN for the company's shares: ISIN NO 0013711713 - New number of shares outstanding: 4,478,412 shares...

MIAMI, Jan. 15, 2026 /PRNewswire/ -- SelfDecode, a leader in AI-driven precision health and genetic analysis, supports the DNA Traits experience offered by MyHeritage, one of the world's largest consumer DNA and family history platforms. MyHeritage serves more than 8 million DNA customers......

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL....

Oslo, Norway, 15 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 January 2026 regarding the resolution by the extraordinary general meeting of the Company to increase the share capital in connection with the issuance of 75 new shares to Abakus Invest AS for purposes of facilitating a reverse share split. The share capital increase referred to above has today been registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). The new shares will be issued and registered in the CSD with ISIN NO...

Oslo, Norway, 14 January 2026: Reference is made to the stock exchange announcement made by Oncoinvent ASA (the "Company") on 8 January 2026 regarding the resolution by the Company's extraordinary general meeting to carry out a reverse share split of the Company's shares. Key information related to the reverse share split, including the relevant key dates that have been determined by the board of directors today in accordance with the resolution by the general meeting, is set out below: · Date on which the corporate action was made public: 18 December 2025 · Reverse split ratio: 100:...

VANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) today announced the planned expansion of its HealthTab™ platform across North East London (NEL), with deployment to an additional 70 community pharmacy sites, building on the success of its NHS-linked cardiovascular programmes delivered in collaboration with Barts Health NHS Trust....

Oslo, Norway, 13 January 2026: Reference is made to the announcement made by Oncoinvent ASA ("Oncoinvent" or the "Company") 31 October 2025 regarding the appointment of Ramzi Amri as the new CEO of the Company as of January 2026. The Board of Directors has resolved to grant Ramzi Amri 5,430,000 share options in the Company under the Company's long term incentive program, each with a strike price of NOK 0.4671, equal to the volume weighted average share price the last day before the grant. Following the grant of the 5,430,000 share options referred to above, Ramzi Amri hold no shares and 5,...

Press release – Oslo, Norway, January 12th, 2026: Photocure announces the publication of the study “Hexaminolevulinate blue light cystoscopy improves bladder cancer detection in comparison to white light cystoscopy: a prospective, comparative, within-patient controlled multicenter phase III bridging study in China” in the Frontiers of Urology journal this week. An abstract with data from this pivotal prospective randomized controlled multi-center Phase 3 trial was first presented at the Congress of the Société Internationale d'Urologie (SIU) in October 2023. Its main objective was to compare...